ETF · iShares
BTEK iShares NASDAQ US Biotechnology UCITS ETF
ISIN IE00BYXG2H39London Stock Exchange: BTEKBlackRock, Inc.
- Healthcare
- ETF
- ISA
- SIPP
- Accumulating
Latest close
LSE£7.92
on
- Ongoing charge
- 0.35% a year
- Fund size
- £1.0bn
As of , at least 15 min delayed
At a glance
As of 13/11/2026, BTEK (iShares NASDAQ US Biotechnology UCITS ETF, ISIN IE00BYXG2H39) closed at £7.92 on the London Stock Exchange. Its ongoing charge is 0.35% a year (about £35 on £10,000). Over the five years to 13/11/2026 its total return was +57.1%, or +22.6% after UK CPIH inflation.
Past returns
- 1 year to 13/11/2026
- +33.2%
- +28.5% after inflation (UK CPIH)
- 3 years to 13/11/2026
- +86.4%
- +68.4% after inflation (UK CPIH)
- 5 years to 13/11/2026
- +57.1%
- +22.6% after inflation (UK CPIH)
£1,000 put in five years ago would have been worth about £1,571 on 13/11/2026 — about £1,226 in today’s spending power, once price rises are taken out. Past performance is not a guide to future returns.
Returns: as reported (delayed data). Inflation: UK CPIH, latest month published.
How we work it out:ReturnsReturns after inflationTotal returnReal returnCPIH
Calendar-year and 12-month returns
Calendar-year returns of iShares NASDAQ US Biotechnology UCITS ETF in pounds (price, with income reinvested in the fund): 2022 −1.6%, 2023 +0.3%, 2024 +2.1%, 2025 +20.4%; 2026 to 13/11/2026 +28.8%. Returns of iShares NASDAQ US Biotechnology UCITS ETF in pounds (price, with income reinvested in the fund) over the 12 months to 30/09/2026: +43.4%; to 30/09/2025: +6.0%; to 30/09/2024: +10.2%; to 30/09/2023: −5.4%; to 30/09/2022: −5.3%.
| Year | Return | After inflation | Return shown as a bar |
|---|---|---|---|
| to | +28.8% | +24.7% | |
| to | +20.4% | +16.3% | |
| to | +2.1% | −1.4% | |
| +0.3% | −3.7% | ||
| −1.6% | −9.9% |
| 12 months to | Return | After inflation |
|---|---|---|
| from | +43.4% | +38.3% |
| from | +6.0% | +1.9% |
| from | +10.2% | +7.4% |
| from | −5.4% | −11.0% |
| from | −5.3% | −13.0% |
As of , inflation: UK CPIH
How we work it out:Calendar-year returnsWhat a calendar-year return isAccumulating and distributing
Risk: volatility and largest fall
Volatility (annualised)
19.0%over 5 years
| 1 year | 19.7% |
|---|---|
| 3 years | 19.3% |
| 5 years | 19.0% |
Annualised from weekly returns. Higher means bumpier.
- Largest fall since November 2021
- −23.4%
- From to
- Lowest 12-month return
- −21.7%
- 12 months to
- Highest 12-month return
- +60.6%
- 12 months to
- Below its highest weekly close since November 2021
- 0.7%
- High of , latest
In words: Volatility of iShares NASDAQ US Biotechnology UCITS ETF in pounds, annualised from weekly returns to 13/11/2026: 19.7% over 1 year, 19.3% over 3 years, 19.0% over 5 years. Largest fall in the price of iShares NASDAQ US Biotechnology UCITS ETF since November 2021, in pounds: −23.4% from 26/07/2024 to 11/04/2025. The lowest 12-month return of iShares NASDAQ US Biotechnology UCITS ETF in pounds (price, with income reinvested in the fund) since January 2021 was −21.7% (12 months to 18/02/2022); the highest was +60.6% (12 months to 03/07/2026). On 13/11/2026 the price of iShares NASDAQ US Biotechnology UCITS ETF was 0.7% below its highest weekly close since November 2021 (30/10/2026), in pounds.
As of , price, with income reinvested in the fund
How we work it out:Risk figuresFallsVolatilityLargest fall
Charges compared with similar funds
- Ongoing charge
- 0.35%
- a year
- On £10,000
- £35
- a year, roughly
- Over five years
- £174
- of £10,000, before growth
- 14 charge less
- 3 the same
- 11 charge more
Ongoing charge of iShares NASDAQ US Biotechnology UCITS ETF 0.35% a year. Compared on 14/11/2026, 11 of the 28 other healthcare funds charge more, 3 the same and 14 less (share classes counted once).
As of
A lower charge is not a promise of a higher return: what the fund holds matters more.
Read more:Ongoing charge (OCF)OCF and TERFee dragHow charges add up
In plain English
iShares NASDAQ US Biotechnology UCITS ETF is an exchange-traded fund (ETF) from iShares, launched in 2017.
It tracks the NASDAQ / Biotechnology.
You buy and sell it through a share-dealing account or platform during stock-market hours, like a share.
Its ongoing charge is 0.35% a year — about £35 a year on every £10,000 invested, taken from the fund's value rather than billed to you.
Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
Healthcare: Pharmaceutical, biotech and medical-equipment companies.
Terms:ETFIndex fundUCITSAccumulating or incomeShare classISIN
Key facts
- Ticker
- BTEK
- ISIN
- IE00BYXG2H39
- Also listed as
- BTEC (London Stock Exchange, US dollars), 2B70 (Xetra, euros)
- Provider
- iShares
- Tracks
- NASDAQ / Biotechnology
- Structure
- ETF
- An exchange-traded fund: bought and sold on the stock exchange through the day, like a share.
- Income
- Accumulating
- Income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
- Ongoing charge
- 0.35% a year · about £35 on £10,000
- Fund size
- £1.0bn
- Launched
- Domicile
- Ireland
- UK reporting fund status
- Yes — on HMRC’s list of reporting funds (list of )
- Reporting fund since . What reporting fund status means
- Can usually be held in
- ISA and SIPP
- Check with your platform: each decides which funds it offers.
- Currency hedged
- No
- Price currency
- Pounds (GBP)
- Category
- Healthcare
Price chart
Over the last year, the closing price went from £6.15 on 14/11/2025 to £7.92 on 13/11/2026 (+28.8%). The lowest close shown was £6.15 on 27/03/2026 and the highest £7.98 on 30/10/2026.
One close a week. Before 31/07/2026 the closes are from the weekly price history for this listing; from then on, the closing prices we have recorded.
As of , at least 15 min delayed
Five years of prices, and after inflation
262 weekly closes, from 12/11/2021 to 13/11/2026. The same history in November 2026 pounds, adjusted with CPIH inflation.
Create a free account to see the 5-year price chart and the after-inflation chart
Sign-up takes an email address. There is no card to enter and nothing to pay.
How we work it out:Prices and returnsNAV and price
What it holds
- Holdings
- 244
- 250 reported in all
- Ten largest
- 48.5%
- of the whole fund
- Effective number of holdings
- 29
- As concentrated as this many equal-sized holdings (how it is worked out)
- Largest holding
- 9.0%
- Gilead Sciences
Top 10 holdings
| Rank# | Holding | Weight as a percentage of the fund |
|---|---|---|
| 1 | Gilead SciencesGILDHealth Care | 8.96% |
| 2 | AmgenAMGNHealth Care | 8.40% |
| 3 | Vertex PharmaceuticalsVRTXHealth Care | 7.88% |
| 4 | ModernaMRNAHealth Care | 6.52% |
| 5 | Regeneron PharmaceuticalsREGNHealth Care | 5.88% |
| 6 | Revolution MedicinesRVMDHealth Care | 2.65% |
| 7 | BiogenBIIBHealth Care | 2.36% |
| 8 | IlluminaILMNHealth Care | 2.07% |
| 9 | Royalty Pharma · Class ARPRXHealth Care | 1.93% |
| 10 | Roivant SciencesROIVHealth Care | 1.81% |
As of , holdings as published
Where it invests
The portfolio by sector, country and type of asset, as a share of the whole fund. Bonds, cash and positions without a classification are shown as they come, not guessed.
By sector
- Health Care99.9%
- Cash and derivatives0.1%
By type of asset
- Equity99.9%
- Cash and money market0.1%
See the full portfolio
Every holding with search and filters, the whole breakdown by sector, country and type of asset, a map of the 100 largest and what changed since .
More of the portfolio
The fund publishes 250 holdings; the ten largest make up 48.5% of it. The fund's portfolio is also split by currency.
Create a free account to see the full holdings list and the currency, maturity and credit-quality breakdowns
Sign-up takes an email address. There is no card to enter and nothing to pay.
Holdings:Compare what it holds with another fundHoldings overlapHow overlap is measured
Funds tracking the same index
3 funds track NASDAQ / Biotechnology, this one included and share classes counted once; their ongoing charges range from 0.35% to 0.40% a year (13/11/2026).
| Fund | Charge | 1 year | 3 years | 5 years |
|---|---|---|---|---|
| Invesco NASDAQ Biotech UCITS ETFAccumulating · 0.40% a year | 0.40% | +33.3% | +86.5% | +57.3% |
| iShares NASDAQ US Biotechnology UCITS ETFThis fundAccumulating · 0.35% a year | 0.35% | +33.2% | +86.4% | +57.1% |
| iShares NASDAQ US Biotechnology UCITS ETF DistDistributing · 0.35% a year | 0.35% | +34.0% | +86.5% | +57.5% |
As of
Nasdaq Biotechnology funds compared: charges, sizes and share classes
Read more:Index fundsTracking differenceHow funds are compared
Other versions of this fund
Risk and return in depth
Sharpe, Sortino and Calmar ratios
Sharpe, Sortino and Calmar ratios over 1, 3 and 5 years, from weekly returns in pounds.
With a free accountRolling returns
The full range of 254 rolling 12-month returns since January 2021, and of 150 rolling three-year returns, in pounds, with how often they were above zero.
With a free accountLargest falls and recoveries
The 3 largest falls since November 2021, in pounds, with how many weeks each took to reach its low and to recover.
With a free account
Create a free account to see the risk ratios, every rolling return and each large fall and its recovery
Sign-up takes an email address. There is no card to enter and nothing to pay.
Moves compared with a similar fund
Correlation and beta of weekly returns in pounds against iShares Core S&P 500 UCITS ETF, over the three years to 13/11/2026 (154 weeks).
Pro
Pro — currently by invitation
Pro includes moves against a comparable fund
Pro is open by invitation while it is being built. There is nothing to buy. To ask about access, email [email protected].
Questions people ask
What is the ongoing charge of BTEK?
The ongoing charge of BTEK is 0.35% a year — about £35 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of iShares NASDAQ US Biotechnology UCITS ETF 0.35% a year. Compared on 14/11/2026, 11 of the 28 other healthcare funds charge more, 3 the same and 14 less (share classes counted once).
What does BTEK track?
BTEK tracks the NASDAQ / Biotechnology.
Is BTEK accumulating or distributing?
BTEK is accumulating: income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
What is the ISIN of BTEK?
The ISIN of BTEK is IE00BYXG2H39. An ISIN identifies one exact share class of a fund; BTEK is its ticker on the London Stock Exchange. The same share class is also listed as BTEC (London Stock Exchange, US dollars) and 2B70 (Xetra, euros).
What does BTEK hold?
As of 06/11/2026, BTEK holds 250 positions, according to its published holdings. The largest is Gilead Sciences at 8.96% of the fund; the ten largest make up 48.5%. Its ten largest holdings are Gilead Sciences (8.96%), Amgen (8.40%), Vertex Pharmaceuticals (7.88%), Moderna (6.52%), Regeneron Pharmaceuticals (5.88%), Revolution Medicines (2.65%), Biogen (2.36%), Illumina (2.07%), Royalty Pharma · Class A (1.93%) and Roivant Sciences (1.81%).
What were BTEK’s returns in each of the last five years?
Calendar-year returns of BTEK in pounds (price, with income reinvested in the fund): 2022 −1.6%, 2023 +0.3%, 2024 +2.1%, 2025 +20.4%; 2026 to 13/11/2026 +28.8%. Past performance is not a guide to future returns.
How has BTEK done after inflation?
Over the five years to 13/11/2026 BTEK’s total return was +57.1%, or +22.6% after UK CPIH inflation. Past performance is not a guide to future returns.
Similar funds
- XWHSXtrackers MSCI World Health Care UCITS ETF0.25% a year · £3.4bn
- IHCUiShares S&P 500 Health Care Sector UCITS ETF0.15% a year · £2.7bn
- DRDRiShares Healthcare Innovation UCITS ETF0.40% a year · £1.3bn
- XSHCXtrackers MSCI USA Health Care UCITS ETF0.12% a year · £1.2bn
- CH5Amundi STOXX Europe 600 Healthcare UCITS ETF -Acc- Capitalisation0.30% a year · £833m
- ESIHiShares MSCIEurope Health Care Sector UCITS ETF AccumEUR0.18% a year · £798m
- 0DW6Amundi MSCI World Health Care UCITS ETF EUR ACC0.30% a year · £792m
- AGESiShares Ageing Population UCITS ETF0.40% a year · £677m
Fund documents and methods
- Fund documents
- Fund page at iShares · Key investor information document (KIID) · Factsheet (links checked )
Methodology:ReturnsCategoriesAll methods
A machine-readable copy of this page: Markdown.